ABSTRACT
Background Cortical demyelinated lesions are prevalent in multiple sclerosis (MS) and associated with disability; their presence on MRI has recently been incorporated into MS diagnostic criteria. Presently, advanced and ultra-high-field MRI — not routinely available in clinical practice — are the most sensitive methods for detection of cortical lesions, and approaches utilizing MRI sequences obtainable in routine clinical practice remain an unmet need.
Objective To assess the sensitivity of the ratio of T1-weighted and T2-weighted (T1/T2) signal intensity for focal cortical lesions in comparison to other established, sensitive, advanced and high-field imaging methods.
Methods 3-tesla (3T) and 7-tesla (7T) MRI collected from 10 adults with MS participating in a natural history study at the National Institutes of Health were included in the study. T1/T2 images were calculated by dividing 3T T1w images by 3T T2w fluid-attenuated inversion recovery (FLAIR) images for each participant. Cortical lesions were identified using 7T T2*w and T1w images and corresponding voxels were assessed on registered 3T images. For each participant, ratios derived from the median signal intensity of nonlesional tissue in the cortical region of the lesion and the median lesional voxel intensity were computed. These values were compared across 3T imaging sequences, including the calculated T1/T2 image, as well as T1w, T2w, and Inversion Recovery Susceptibility Weighted Imaging with Enhanced T2 weighting (IR-SWIET) images.
Results 614 cortical lesions were identified on 7T images. 3T T1/T2 images demonstrated a larger contrast between median nonlesional cortical signal intensity and median cortical lesion signal intensity (median ratio = 1.29, range 1.19 – 1.38) when compared to T1w (1.01, 0.97 – 1.10, p<0.002), T2w (1.17, 1.07 – 1.26, p<0.002), and IR-SWIET (1.21, 1.01 – 1.29, p<0.03).
Conclusion T1/T2 images are sensitive to cortical lesions. Approaches incorporating T1/T2 could improve the accessibility of cortical lesion detection in research settings and clinical practice.
Competing Interest Statement
Disclosures: A.R. Manning, M.K. Schindler, G. Nair, and P. Parvathaneni report no disclosures relevant to the manuscript. D.S. Reichs lab has received research support from Abata Therapeutics, Sanofi-Genzyme, and Vertex Pharmaceuticals. R.T. Shinohara reports consulting income from Octave Biosciences and has received compensation for scientific reviewing from the American Medical Association, the Department of Defense, the Emerson Collective, and the National Institutes of Health. A.J. Solomon reports consulting or advisory board compensation from EMD Serono, Genentech, Biogen, Alexion, Celgene, Greenwhich Bioschiences, TG Therapeutics, and Octave Bioscience, non-promotional speaking for EMD Serono, research funding from Bristol Myers Squibb and Biogen, contracted research for Sanofi, Biogen, Novartis, Actelion, Genentech/Roche, and medicolegal consultations including expert witness testimony.
Funding Statement
This research was supported by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) (R01 NS112274), and in part by the Intramural Research Program of the NINDS, National Institutes of Health (NIH). E.S. Beck is also supported by a Career Transition Fellowship from the National Multiple Sclerosis Society (TA-1805-31038).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board Office of the National Institutes of Health Intramural Research Program gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Upon publication and for one year thereafter, deidentified participant level data, including MR images, may be made available upon reasonable request.
